PI3Kγ inhibition: towards an 'aspirin of the 21st century'?

Class IB phosphatidylinositol 3-kinase p110γ (PI3Kγ) has gained increasing attention as a promising drug target for the treatment of inflammatory disease. Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kγ inhibitors, opening up potentially huge opportunities for these drugs. Several companies have been pursuing small-molecule PI3Kγ inhibitor projects, but none of them has progressed to the clinic yet. Here, we discuss the insights gained so far and the main challenges that are emerging on the path to developing PI3Kγ inhibitors for the treatment of human disease.

[1]  M. Sunagawa,et al.  Angiotensin II stimulation of Ca2+-channel current in vascular smooth muscle cells is inhibited by lavendustin-A and LY-294002 , 1999, Pflügers Archiv.

[2]  D. F. Barber,et al.  Class IB-Phosphatidylinositol 3-Kinase (PI3K) Deficiency Ameliorates IA-PI3K-Induced Systemic Lupus but Not T Cell Invasion1 , 2006, The Journal of Immunology.

[3]  Christine Tkaczyk,et al.  Integrated signalling pathways for mast-cell activation , 2006, Nature Reviews Immunology.

[4]  P. Wipf,et al.  Chemistry and biology of wortmannin. , 2005, Organic & biomolecular chemistry.

[5]  Punit Marathe,et al.  N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.

[6]  E. Hirsch,et al.  Ablation of Phosphoinositide 3-Kinase-γ Reduces the Severity of Acute Pancreatitis , 2004 .

[7]  L. Silengo,et al.  Protection from angiotensin II–mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ , 2005, The Journal of experimental medicine.

[8]  J. Gutkind,et al.  Phosphoinositide 3-Kinase γ Is a Mediator of Gβγ-dependent Jun Kinase Activation* , 1998, The Journal of Biological Chemistry.

[9]  C. Rommel,et al.  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. , 2006, Journal of medicinal chemistry.

[10]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[11]  E. Grant,et al.  Essential Role for the C5a Receptor in Regulating the Effector Phase of Synovial Infiltration and Joint Destruction in Experimental Arthritis , 2002, The Journal of experimental medicine.

[12]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[13]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[14]  C. Benoist,et al.  Mast Cells: A Cellular Link Between Autoantibodies and Inflammatory Arthritis , 2002, Science.

[15]  E. Prigmore,et al.  Requirement for PI 3-kinase γ in macrophage migration to MCP-1 and CSF-1 , 2003 .

[16]  S. Volinia,et al.  Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. , 1995, Science.

[17]  P. Finan,et al.  PI3-Kinase Inhibition , 2006 .

[18]  R. Taussig,et al.  Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. , 1994, The Journal of biological chemistry.

[19]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[20]  Z. Li,et al.  Action mechanisms and structure-activity relationships of PI3Kgamma inhibitors on the enzyme: a molecular modeling study. , 2006, European journal of medicinal chemistry.

[21]  C. Kahn,et al.  Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.

[22]  캐서린 레블랑,et al.  5-phenylthiazole derivatives and use as ??3 kinase inhibitors , 2003 .

[23]  E. Hirsch,et al.  Resistance to thromboembolism in PI3Kγ‐deficient mice , 2001 .

[24]  P. Hawkins,et al.  The Gβγ Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101 , 1997, Cell.

[25]  M. Mareel,et al.  Tumour biology. Weakening link to colorectal cancer , 2001 .

[26]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[27]  D. Clapham,et al.  Ion channel regulation by G proteins. , 1995, Physiological reviews.

[28]  P. Finan,et al.  Airway inflammation: chemokine‐induced neutrophilia and the class I phosphoinositide 3‐kinases , 2005, European journal of immunology.

[29]  P. Finan,et al.  Phosphoinositide 3-Kinase γ Is an Essential Amplifier of Mast Cell Function , 2002 .

[30]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[31]  D. Malan,et al.  Phosphoinositide 3‐kinase γ controls autonomic regulation of the mouse heart through Gi‐independent downregulation of cAMP level , 2005, FEBS letters.

[32]  C. Martínez-A,et al.  Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. , 2004, Immunity.

[33]  J. Penninger,et al.  The role of endothelial PI3Kgamma activity in neutrophil trafficking. , 2005, Blood.

[34]  C. Rommel,et al.  Strategies for chemokine antagonists as therapeutics. , 2003, Seminars in immunology.

[35]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[36]  D. Siderovski,et al.  G-protein signaling: back to the future , 2005, Cellular and Molecular Life Sciences.

[37]  A. Maghazachi,et al.  Recruitment of Pleckstrin and Phosphoinositide 3-Kinase γ into the Cell Membranes, and Their Association with Gβγ After Activation of NK Cells with Chemokines , 1999, The Journal of Immunology.

[38]  M. J. Fry,et al.  The phosphoinositide (PI) 3-kinase family , 2003, Journal of Cell Science.

[39]  C. Rommel,et al.  Chemokine inhibition--why, when, where, which and how? , 2004, Biochemical Society transactions.

[40]  R. Horuk,et al.  The clinical potential of chemokine receptor antagonists. , 2005, Pharmacology & therapeutics.

[41]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[42]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[43]  Mark C. Fishman,et al.  Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.

[44]  Zhong Li,et al.  Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta) , 2006, Journal of molecular modeling.

[45]  S. Steinberg.  PI3King the L-type calcium channel activation mechanism. , 2001, Circulation research.

[46]  R. Horuk,et al.  Chemokines, chemokine receptors and small-molecule antagonists: recent developments. , 2002, Trends in pharmacological sciences.

[47]  K. Okkenhaug,et al.  Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. , 2005, Blood.

[48]  M. Teixeira,et al.  Phosphoinositide‐3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation , 2005, Journal of leukocyte biology.

[49]  C. Rommel,et al.  Fishing for Pharmaceutically Relevant Phosphoinositide-Binding Proteins Using Chemical Proteomics , 2005 .

[50]  A. Robertson,et al.  PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.

[51]  D. Zhelev,et al.  Chemoattractant receptor-stimulated F-actin polymerization in the human neutrophil is signaled by 2 distinct pathways. , 2003, Blood.

[52]  P. Finan,et al.  Therapeutic potential of phosphoinositide 3-kinase inhibitors. , 2003, Chemistry & biology.

[53]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[54]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[55]  Min Zhao,et al.  Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-γ and PTEN , 2006, Nature.

[56]  D. F. Barber,et al.  Phosphatidylinositol 3-Kinase Regulates the CD4/CD8 T Cell Differentiation Ratio1 , 2003, The Journal of Immunology.

[57]  S. Abramson,et al.  The neutrophil in rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.

[58]  P. Wipf,et al.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. , 2004, Molecular cancer therapeutics.

[59]  P. Hawkins,et al.  A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein βγ subunits , 1994, Cell.

[60]  A. Koch,et al.  Chemokines and chemokine receptors in rheumatoid arthritis. , 2003, Seminars in immunology.

[61]  M SoestvanR.W.,et al.  Liphagal, a Selective Inhibitor of PI3 Kinase ά Isolated from the Sponge Aka coralliphaga: Structure Elucidation and Biomimetic Synthesis , 2006 .

[62]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[63]  U. Eriksson,et al.  Phosphoinositide 3-Kinase &ggr;–Deficient Mice Are Protected From Isoproterenol-Induced Heart Failure , 2003 .

[64]  Christopher J. Helal.  Discovery and SAR of 2‐Aminothiazole Inhibitors of Cyclin‐Dependent Kinase 5/p25 as a Potential Treatment for Alzheimer′s Disease. , 2005 .

[65]  Punit Marathe,et al.  Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. , 2002, Journal of medicinal chemistry.

[66]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[67]  E. Vigorito,et al.  A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation , 2002, The Journal of experimental medicine.

[68]  P. Hawkins,et al.  Characterizing the Interactions between the Two Subunits of the p101/p110γ Phosphoinositide 3-Kinase and Their Role in the Activation of This Enzyme by Gβγ Subunits* , 1999, The Journal of Biological Chemistry.

[69]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[70]  R. Pope.  Apoptosis as a therapeutic tool in rheumatoid arthritis , 2002, Nature Reviews Immunology.

[71]  P. Finan,et al.  Essential role for the p110δ phosphoinositide 3-kinase in the allergic response , 2004, Nature.

[72]  K. Okkenhaug,et al.  PI3K in lymphocyte development, differentiation and activation , 2003, Nature Reviews Immunology.

[73]  J. Ihle,et al.  Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110δ in Signaling by the B-Cell Receptor Complex , 2002, Molecular and Cellular Biology.

[74]  L. Pirola,et al.  Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. , 1998, Science.

[75]  J. Rohn,et al.  Gene Targeting Attention to Detail , 2004, Cell.

[76]  W. Kuziel,et al.  Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis , 2000, The Journal of experimental medicine.

[77]  L. Silengo,et al.  PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.

[78]  C. Rommel,et al.  Phosphoinositide 3-kinases as targets for therapeutic intervention. , 2004, Current pharmaceutical design.

[79]  Peter J. Alaimo,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. , 2004, Bioorganic & medicinal chemistry.

[80]  D. T. Dudley,et al.  Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinaseγ , 2007 .

[81]  A. Gilman,et al.  Activation of phospholipase C-beta 2 mutants by G protein alpha q and beta gamma subunits. , 1993, The Journal of biological chemistry.

[82]  Christopher B. Cooper,et al.  Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. , 2004, Bioorganic & medicinal chemistry letters.

[83]  B. Nürnberg,et al.  Phosphoinositide 3-Kinase γ Mediates Angiotensin II-induced Stimulation of L-type Calcium Channels in Vascular Myocytes* , 2001, The Journal of Biological Chemistry.

[84]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[85]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[86]  P. Hawkins,et al.  Activation of Phosphoinositide 3-Kinase γ by Ras , 2002, Current Biology.

[87]  S. Ward.  Do phosphoinositide 3-kinases direct lymphocyte navigation? , 2004, Trends in immunology.

[88]  A. Gilman,et al.  G proteins. , 1992, Trends in biochemical sciences.

[89]  Dianqing Wu,et al.  Roles of PLC-β2 and -β3 and PI3Kγ in Chemoattractant-Mediated Signal Transduction , 2000 .

[90]  Ping Chen,et al.  Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). , 2003, Bioorganic & medicinal chemistry letters.

[91]  A. Robertson,et al.  Preparation of morpholinyl and pyridinyl substituted heterobicyclic ketones as selective inhibitors of phosphoinositide 3-kinase beta for use against thrombosis , 2004 .

[92]  D. F. Barber,et al.  PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus , 2005, Nature Medicine.

[93]  W L Stanford,et al.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. , 2000, Science.

[94]  S. Ward,et al.  Activation of Phosphoinositide 3-Kinases by the CCR4 Ligand Macrophage-Derived Chemokine Is a Dispensable Signal for T Lymphocyte Chemotaxis1 , 2004, The Journal of Immunology.

[95]  K. Okkenhaug,et al.  Cutting Edge: Differential Roles for Phosphoinositide 3-Kinases, p110γ and p110δ, in Lymphocyte Chemotaxis and Homing1 , 2004, The Journal of Immunology.

[96]  Silvano Sozzani,et al.  Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation , 2000 .

[97]  Lewis C. Cantley,et al.  The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function* , 1999, The Journal of Biological Chemistry.

[98]  M. Wymann,et al.  Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. , 2005, Current opinion in cell biology.

[99]  R. Shenkar,et al.  Involvement of Phosphoinositide 3-Kinases in Neutrophil Activation and the Development of Acute Lung Injury1 , 2001, The Journal of Immunology.

[100]  D. Fruman,et al.  Phosphoinositide 3-kinase: diverse roles in immune cell activation. , 2004, Annual review of immunology.

[101]  R. Wetzker,et al.  Tissue distribution and subcellular localization of a G-protein activated phosphoinositide 3-kinase. An immunohistochemical study. , 1998, Cellular and molecular biology.

[102]  P. Hawkins,et al.  Phosphoinositide 3‐kinase‐dependent activation of Rac , 2003, FEBS letters.

[103]  R. Firtel,et al.  Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[104]  G. Esposito,et al.  Cardiac hypertrophy: role of G protein-coupled receptors. , 2002, Journal of cardiac failure.

[105]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[106]  D. Staunton,et al.  Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement , 2003, The Journal of Immunology.

[107]  D. Malan,et al.  Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. , 2003, Cardiovascular research.

[108]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[109]  C. Rommel,et al.  Involvement of Phosphoinositide 3-Kinase γ, Rac, and PAK Signaling in Chemokine-induced Macrophage Migration* , 2004, Journal of Biological Chemistry.